COVID-19 Pandemic Delays FDA Review of Vaping Products

COVID-19大流行延迟 FDA 真空产品审查

2020-04-25 09:30:11 Drugs

本文共305个字,阅读需1分钟

FRIDAY, April 24, 2020 -- A review of vaping products has been delayed by the COVID-19 outbreak, the U.S. Food and Drug Administration announced Thursday. The agency said that a federal court granted its request to delay the May 12 deadline for companies to submit applications for vaping products to Sept. 9, the Associated Press reported. The FDA said the pandemic made it difficult for its staff and companies to meet the original deadline for the review that is part of the agency's plans to regulate vaping products such as electronic cigarettes and flavored solutions. Last year, health advocacy groups sued the FDA to speed up its review of vaping products and the court ruled that the agency must set the May 12 deadline for product applications, the AP reported. AP News Article © 2020 HealthDay. All rights reserved. Posted: April 2020
美国食品和药物管理局( FDA )周四宣布,2020年4月24日星期五—— COVID-19疫情推迟了对 vaping 产品的审查。 据美联社报道,该机构说,一家联邦法院批准了将5月12日公司提交虚假产品申请的最后期限推迟到9月9日的请求。 FDA 表示,这场大流行使得其员工和公司很难在原定的最后期限之前完成审查,这是 FDA 监管电子烟和调味品解决方案等吸食产品计划的一部分。 据美联社报道,去年,健康倡导组织起诉 FDA 加快对 vaping 产品的审查,法院裁定 FDA 必须设定5月12日的产品申请截止日期。 美联社新闻文章 ©2020 HealthDay 。保留所有权利。 张贴日期:二零二零年四月

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文